Biologics for Immuno Disorders: 70.7% of denials overturned
In 92 California IMR decisions from 2006 to 2025, reviewers overturned 65 (70.7%). In the last five years: 73.5% of 68. 84 were medical-necessity disputes, 8 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 8 | 75.0% |
| 2022 | 8 | 87.5% |
| 2023 | 9 | 66.7% |
| 2024 | 10 | 80.0% |
| 2025 | 33 | 69.7% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 40 | 62.5% | 70.7% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 27 | 85.2% | 70.7% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 14 | 71.4% | 70.7% |
| Step therapy or fail-firstThe findings mention a fail-first requirement. | 8 | 50.0% | 70.7% |
| FDA approval or off-label use discussedThe findings discuss the FDA label status of the treatment. | 6 | 50.0% | 70.7% |
| Alternatives contraindicatedThe findings mention a contraindication to the plan's preferred option. | 5 | 0.0% | 70.7% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 5 | 0.0% | 70.7% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that a patient has requested authorization and coverage for Uplizna.The records indicate that this patient presents with a history of neuromyelitis optica spectrum disorder (NMOSD). The patient has tested positive for a disease specific antibody. The patient has tried and failed treatment with intravenous corticosteroids. The patient’s provider has recommended treatment with Uplizna. One study noted …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary:A patient has requested authorization and coverage for dosage escalation of Tremfya One-Press 100 mg/mL to once every four weeks. Tremfya (guselkumab) is a U.S. Food and Drug Administration approved biologic therapy for psoriatic arthritis. Clinical guidelines support a treat-to-target approach, with adjustment of therapy in patients with persistent disease activity …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary:A patient has requested authorization and coverage for Benlysta, or alternatively Saphnelo. Benlysta (belimumab) and Saphnelo (anifrolumab) are U.S. Food and Drug Administration approved therapies for the treatment of systemic lupus erythematosus in patients with persistent disease activity despite standard therapy. Clinical guidelines support the use of biologic add on therapy …”
And one the reviewer upheld
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: The parent of a patient has requested authorization and coverage for Olumiant. Olumiant is U.S. Food and Drug Administration (FDA)-approved for adult patients with severe alopecia areata. This patient presents with moderate-to-severe alopecia areata. The patient previously underwent treatment. The patient experienced significantly elevated creatine kinase (CK) and had to …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Biologics denials for Immuno Disorders overturned?
In 92 California IMR decisions from 2006 to 2025, reviewers overturned 65 (70.7%). In the last five years: 73.5% of 68. 84 were medical-necessity disputes, 8 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.